Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 17/20 | 0.80 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.80 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2109638 | 1.00 | ALOX5 (0.80) | ALOX5EPHX2HRH1ACACBACACA | |
| Atreleuton SCHEMBL2107799 | 0.89 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| Atreleuton SCHEMBL504818 | 0.89 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| Atreleuton SCHEMBL2108309 | 0.89 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8303838 | 0.88 | ALOX5 (0.79) | ALOX5EPHX2HRH1ACACBACACA | |
| SCHEMBL8303836 | 0.88 | ALOX5 (0.79) | ALOX5EPHX2HRH1ACACBACACA | |
| SCHEMBL8304304 | 0.87 | ALOX5 (0.77) | ALOX5EPHX2HRH1ACACBACACA | |
| SCHEMBL8309174 | 0.86 | ALOX5 (0.76) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8309173 | 0.86 | ALOX5 (0.76) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8307175 | 0.85 | ALOX5 (0.65) | ALOX5EPHX2HRH1ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0667855-B1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 1999-03-24 | — | — | EP | claimed |
| US-8158362-B2 | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype | DECODE GENETICS EHF. (IS) | 2012-04-17 | — | — | US | disclosed |
| US-7851486-B2 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS EHF. (IS) | 2010-12-14 | — | — | US | disclosed |
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | DECODE GENETICS EHF. (IS) | 2010-08-26 | — | — | US | disclosed |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | DECODE GENETICS EHF. (IS) | 2008-11-27 | — | — | US | disclosed |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS, INC. (IS) | 2007-12-06 | — | — | US | disclosed |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | DECODE GENETICS, INC. (IE) | 2006-01-26 | — | — | US | disclosed |
| US-20050282855-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS EHF. (IS) | 2005-12-22 | — | — | US | disclosed |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | DECODE GENETICS EHF. (IS) | 2005-05-26 | — | — | US | disclosed |
| EP-0667855-B1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5616596-A | Substituted arylalkynyl-and heteroarylalkynl-N-hydroxyurea inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1997-04-01 | — | — | US | disclosed |
| US-5506261-A | Substituted aryl- and heteroarylalkenyl-N-hydroxyurea inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1995030671-A1 | SUBSTITUTED ARYL- AND HETEROARYLALKENYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1995-11-16 | — | — | WO | disclosed |
| US-5288751-A | [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | ALOX15B, ALOX15, ALOX5 | ALOX5 3/4885EPHX2 116/4885HRH1 1549/4885 |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | ALOX15B, ALOX15, ALOX5 | ALOX5 3/4885EPHX2 116/4885HRH1 1549/4885 |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | PLAAT3, PLAAT2, PLA2G7 | ALOX5 14/4885EPHX2 168/4885HRH1 3582/4885 |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | ALOX5, ALOX15, ALOX12 | ALOX5 1/4885EPHX2 136/4885HRH1 1466/4885 |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | PLAAT3, PLAAT2, PLA2G7 | ALOX5 13/4885EPHX2 139/4885HRH1 3646/4885 |
| US-20050282855-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | PLAAT3, PLAAT2, PLA2G7 | ALOX5 49/4885EPHX2 257/4885HRH1 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.